PofoliaShared via Pofolia

Pediatric Blood & Cancer· 2026Q1

Proton Radiotherapy Decreases Incidence of Radiation‐Induced Second Malignant Neoplasms Compared to Photon Radiotherapy in Patients With Retinoblastoma

Sayeh Fattahi, Daniel George Packard, Beow Yong Yeap, Roshan V. Sethi et al.

Short summary

Proton radiotherapy resulted in a 0% incidence of in-field second malignant neoplasms (SMNs) at 15 years compared to 11.1% with photon radiotherapy in retinoblastoma patients (p = 0.005).

AI-generated from the title and abstract; the full text is not read.

Key points

  • Proton radiotherapy yielded 0% in-field SMN incidence at 15 years vs. 11.1% for photon radiotherapy (p = 0.005).
  • Three additional SMNs occurred >20 years post-photon radiotherapy.
  • Study included 42 patients in the photon cohort and 66 in the proton cohort.
  • Median follow-up was 28.7 years for photon and 18.2 years for proton therapy.

AI-generated from the title and abstract; the full text is not read.

Abstract

Retinoblastoma is the most common primary intraocular neoplasm in children. Use of radiotherapy has decreased due to the incidence of second malignant neoplasms (SMNs). In our study, photon (n = 42) and proton (n = 66) radiotherapy cohorts had median follow-up of 28.7 and 18.2 years, respectively. The majority of patients (74%) had bilateral disease at diagnosis. Proton radiotherapy is associated with significantly lower cumulative incidence of in-field SMNs (0% vs. 11.1% at 15 years, p = 0.005), with three additional cases occurring > 20 years after photon radiotherapy. These findings suggest that when radiotherapy is indicated for patients with bilateral retinoblastoma, proton radiotherapy should be considered when feasible.

The authors' abstract, as published at the source. Pediatric Blood & Cancer, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Ophthalmology

OphthalmologyMedicine